Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO.
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
21
02
2023
revised:
24
02
2023
accepted:
25
02
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
In November 2022, the findings of the Avoiding Late Diagnosis of Ovarian cancer (ALDO) study were published. Subsequent media coverage suggested that investigators had found a safe alternative to risk-reducing bilateral salpingoophorectomy (rrBSO) in patients with pathogenic
Identifiants
pubmed: 36938343
doi: 10.1016/j.gore.2023.101157
pii: S2352-5789(23)00026-7
pmc: PMC10020112
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101157Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Clin Cancer Res. 2017 Jul 15;23(14):3628-3637
pubmed: 28143870
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10
pubmed: 34171390
J Clin Oncol. 2017 May 1;35(13):1411-1420
pubmed: 28240969
JAMA Oncol. 2021 Aug 01;7(8):1203-1212
pubmed: 34081085
J Med Genet. 2022 Nov 1;:
pubmed: 36319079
Ann Oncol. 2013 Dec;24 Suppl 10:x16-21
pubmed: 24265397
Gynecol Oncol. 2019 Nov;155(2):270-274
pubmed: 31500890
Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20
pubmed: 17645503
JAMA. 2018 Feb 13;319(6):595-606
pubmed: 29450530
Obstet Gynecol. 2011 Dec;118(6):1212-1221
pubmed: 22105249